{"id":5911,"date":"2014-10-02T09:28:10","date_gmt":"2014-10-02T13:28:10","guid":{"rendered":"https:\/\/www.bu.edu\/alzresearch\/?page_id=5911"},"modified":"2015-05-22T15:03:25","modified_gmt":"2015-05-22T19:03:25","slug":"expedition3","status":"publish","type":"page","link":"https:\/\/www.bu.edu\/alzresearch\/education-program\/recruiting-studies\/completed\/expedition3\/","title":{"rendered":"The Expedition 3 Study"},"content":{"rendered":"

\"Expedition<\/a><\/h1>\n

The Expedition 3 Study<\/h1>\n

This phase 3, placebo-controlled, double-blind, parallel-group, bayesian adaptive randomized design and dose regimen-finding study to evaluate safety, tolerability and efficacy of Solanezumab<\/b> in subjects with early Alzheimer’s disease.<\/p>\n

The study drug is called\u00a0Solanezumab<\/b>, a humanized monoclonal antibody that targets amyloid beta.<\/p>\n

What happens during the study?<\/h3>\n

A telephone screening will be conducted to determine if you are eligible to come in for an in-person screening visit. This screening visit to determine if you are eligible for the study. As part of the screening procedures, you will have a MRI and a PET scan using Amyvid, an FDA-approved compound to determine the presence or absence of amyloid deposits in the brain.<\/p>\n

Patients enrolled in the study receive either the study drug, Solanezumab, or placebo intravenously every four weeks for a period of 18 months.<\/p>\n

They will have tests of memory to assess the effects of the study drug, along with MRIs, physical examinations and EKGs to assess for drug safety.<\/p>\n

Where is this study taking place?<\/h3>\n

Boston University Medical Center<\/a><\/p>\n

Meet the team<\/h3>\n

Robert A. Stern, PhD<\/a> – Principal Investigator
\nWendy Qiu, MD, PhD<\/a> – Study Physician
\nJesse Mez, MD<\/a> – Study Physician
\nJane Mwicigi, MPH<\/a> – Study Coordinator
\nDiane Essis<\/a> – Recruitment Coordinator
\nMeenakshi Chivukula<\/a> – Research Assistant<\/p>\n

More information<\/h3>\n

Please call 617-414-1077<\/b> or email JoinADC@bu.edu<\/a> for more information and to participate.<\/p>\n

Sponsor – Eli Lilly and Co.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Expedition 3 Study This phase 3, placebo-controlled, double-blind, parallel-group, bayesian adaptive randomized design and dose regimen-finding study to evaluate safety, tolerability and efficacy of Solanezumab in subjects with early Alzheimer’s disease. The study drug is called\u00a0Solanezumab, a humanized monoclonal antibody that targets amyloid beta. What happens during the study? A telephone screening will be […]<\/p>\n","protected":false},"author":7513,"featured_media":0,"parent":86,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/pages\/5911"}],"collection":[{"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/users\/7513"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/comments?post=5911"}],"version-history":[{"count":39,"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/pages\/5911\/revisions"}],"predecessor-version":[{"id":7195,"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/pages\/5911\/revisions\/7195"}],"up":[{"embeddable":true,"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/pages\/86"}],"wp:attachment":[{"href":"https:\/\/www.bu.edu\/alzresearch\/wp-json\/wp\/v2\/media?parent=5911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}